UC Davis UC Davis Previously Published Works

Title

Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. J. Fungi 2016, 2, 25.

Permalink

https://escholarship.org/uc/item/5049p50w

Journal

Journal of Fungi, 2(4)

ISSN

2309-608X

Authors

Stewart, Ethan R Thompson, George R

Publication Date 2016

DOI 10.3390/jof2040027

Peer reviewed



Correction



Correction: Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. *J. Fungi* 2016, *2*, 25.

Ethan R. Stewart¹ and George R. Thompson III^{1,2,*}

- ¹ Department of Internal Medicine, Division of Infectious Diseases, Davis Medical Center, 4150 V Street, Suite G500, Sacramento, CA 95817, USA; ethanstewart@gmail.com
- ² Department of Medical Microbiology and Immunology, University of California, Rm. 3138, Tupper Hall, One Shields Ave, Davis, CA 95616, USA
- * Correspondence: grthompson@ucdavis.edu; Tel.: +1-916-734-3815; Fax: +1-530-752-8692

Academic Editor: William J. Steinbach Received: 3 November 2016; Accepted: 4 November 2016; Published: 4 November 2016

The authors of the published paper [1] would like to correct Table 1. The sixth row in the second column should have been Amphotericin B Lipid Complex (ABLC). Therefore, Table 1 should read as follows:

Recommendation	Drug	Dosing	Comments
Primary	Voriconazole	6 mg/kg IV every 12 h times two then 4 mg/kg IV every 12 h	Oral therapy at mg/kg dosing or 200–300 mg every 12 h; TDM required
Alternatives	Lipsosomal amphotericin B (L-AMB)	3–5 mg/kg/day IV	
	Isavuconazole	200 mg every 8 h IV or PO times six then 200 mg daily IV or PO	Need for TDM remains undefined
	Voriconazole plus Anidulafungin	Vorizonazole as above plus Anidulafungin 200 mg IV daily times one then 100 mg IV daily	Combination therapy considered in severe disease and with hematologic malignancy
	Amphotericin B Lipid Complex (ABLC)	5 mg/kg/day IV	
Secondary	Caspofungin	70 mg IV daily times one then 50 mg IV daily	Monotherapy as salvage
	Posaconazole	Oral suspension: 200 mg PO every 8 h, Tablet: 300 mg PO every 12 h times two then 300 mg PO daily, Intravenous: 300 mg IV every 12 h times two then 300 mg IV daily	Caution in use of tablet formulation with acid suppression; TDM required
	Itraconazole	200 mg PO every 12 h	TDM required

 Table 1. Treatment recommendations for invasive aspergillosis.

We apologize for any inconvenience caused to readers. The manuscript will be updated and the original will remain available on the article webpage.

Conflicts of Interest: The authors declare no conflict of interest.

Reference

1. Stewart, E.R.; Thompson, G.R. Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence. *J. Fungi* **2016**, *2*, 25. [CrossRef]



© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).